Scientific exchange · Dr. Chloé Fischer

15 Sept 2026 · Virtual · Dr. Chloé Fischer, Kyoto University Hospital · MSL James Whitfield · Vantrexa

DraftVeeva CRMENG-0093—

Capture insight from this engagement

Location: Kyoto University Hospital
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients
Comparator checkpoint monotherapy
Chemotherapy-free first line

Scientific content used

VOYAGE-1 pivotal data summary
PD-L1 testing pathway infographic

Questions raised

No questions recorded.

Notes

Scientific exchange with pathologist at Kyoto University Hospital. Discussed elderly / ecog 2 patients, comparator checkpoint monotherapy, chemotherapy-free first line.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

1Draft
2Submitted
3Reviewed

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Available after review.

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0093

Audit history (0)

All create, update and approval events for this record

No audit events in sample data